Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Completed 2

Sponsor Class

NIH 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 2Lymphoid 2Dermatologic 1

Conditions

Breast Neoplasms 7Lymphoma 6Lymphoma, T-Cell 4Lymphoma, Mantle-Cell 4Lymphoma, Large B-Cell, Diffuse 4Burkitt Lymphoma 4Neuroblastoma 3Lymphoma, Large-Cell, Anaplastic 3Leukemia, Myeloid, Acute 3Immunoblastic Lymphadenopathy 3Head and Neck Neoplasms 3Waldenstrom Macroglobulinemia 2Triple Negative Breast Neoplasms 2Squamous Cell Carcinoma of Head and Neck 2Small Cell Lung Carcinoma 2Prostatic Neoplasms 2Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Pancreatic Neoplasms 2Ovarian Neoplasms 2Multiple Myeloma 2Lymphoma, Non-Hodgkin 2Lymphoma, Follicular 2Lymphoma, B-Cell, Marginal Zone 2Lung Neoplasms 2Leukemia, Lymphocytic, Chronic, B-Cell 2Hodgkin Disease 2Gastrointestinal Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Advanced Solid Tumors 2

Interventions

Cyclophosphamide 25fludarabine phosphate 22Peripheral Blood Stem Cell Transplantation 22Whole-Body Irradiation 15Etoposide 13Cyclosporine 13Mycophenolic Acid 12Busulfan 12Tacrolimus 11Filgrastim 11Antilymphocyte Serum 11Methotrexate 9Prednisone 8Dexamethasone 8nelarabine 7Radiotherapy 7Doxorubicin 7Vincristine 6Methylprednisolone 6Calcium Dobesilate 6Vorinostat 5Paclitaxel 5Lenalidomide 5Everolimus 5Carboplatin 5Bortezomib 5merphos 4aldesleukin 4Therapeutics 4Rituximab 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Completed × Precursor T-Cell Lymphoblastic Leukemia-Lymphoma × MLN 8237 × Clear all
NCT01567709 2018-04-11

Alisertib in Combination With Vorinostat in Treating Patients With Relapsed or Recurrent Hodgkin Lymphoma, B-Cell Non-Hodgkin Lymphoma, or Peripheral T-Cell Lymphoma

National Cancer Institute (NCI)

Phase 1 Completed
34 enrolled
DermatologicLymphoidOther hematologic neoplasm

Burkitt Lymphoma, Hodgkin Disease, Immunoblastic Lymphadenopathy, Leukemia, Hairy Cell, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Waldenstrom Macroglobulinemia, Mycosis Fungoides, Sezary Syndrome, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, T-Cell, Lymphoma, Large-Cell, Immunoblastic, Lymphoma, T-Cell, Cutaneous, Lymphoma, Large-Cell, Anaplastic, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell, Leukemia, Large Granular Lymphocytic, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma, Intraocular Lymphoma

NCT01466881 2016-03-10

Alisertib in Treating Patients With Relapsed or Refractory Peripheral T-Cell Non-Hodgkin Lymphoma

National Cancer Institute (NCI)

Phase 2 Completed
42 enrolled 10 charts
LymphoidOther hematologic neoplasm

Immunoblastic Lymphadenopathy, Lymphoma, Non-Hodgkin, Lymphoma, T-Cell, Lymphoma, Large-Cell, Anaplastic, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma, Lymphoma, Extranodal NK-T-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡